Abstract. The progression of many solid tumors is characterized by the release of tumor-associated proteases, such as cancer procoagulant, MMP2 and MMP7. consequently, the detection of tumor-specific proteolytic activity in serum specimens has recently been proposed as a new diagnostic tool in oncology. However, tumor-associated proteases are highly diluted in serum specimens and it is challenging to identify substrates that are specifically cleaved. In this study, we describe the systematic optimization of a synthetic peptide substrate using a positional scanning synthetic combinatorial library (PS-ScL) approach. The initial reporter peptide (RP) comprises of the cleavage site, WKPyDAAD, that is part of the coagulation factor X, the natural substrate of the tumorassociated cysteine protease cancer procoagulant (Ec 3.4.22.26). Specifically, the amino acid substitution of aspartatic acid (D) in position P1' against asparagine (N) improved the processing of respective RPs in serum specimens from patients with colorectal tumors compared to healthy controls. Proteolytic fragments of RPs accumulated during prolonged incubation with serum specimens and were quantified with matrixassisted laser desorption/ionization time-of-flight mass spectrometry. Finally, the optimized RP with the cleaved motif WKPyNAAD was combined with the RPs, VPLSLTMg and IPVSLRSg, that were cleaved by the tumor-associated proteases, MMP2 and MMP7, respectively. The diagnostic accuracy of MS-based protease profiling was evaluated for this triplex RP mix in a cohort of 50 serum specimens equally divided into colorectal cancer patients and healthy control individuals. Multiparametric analysis showed an AUc value of 0.90 for the receiver operating characteristic curve and was superior to the classification accuracy of the single markers. Our results demonstrate that RPs for MS-based protease profiling can systematically be optimized with a PS-ScL. Furthermore, the combination of different RPs can additionally increase the classification accuracy of functional protease profiling, and this in turn could lead to improved diagnosis, monitoring and prognosis of malignant disease.
Introduction
Proteases play an important role in different biological processes including cell differentiation, tissue remodelling, haemostasis, immunity, angiogenesis, apoptosis and malignant disease (1) . Specifically for solid tumors, proteases are wellknown factors for promoting local progression and distant metastasis, and there is increasing evidence that proteases also have key functions in the early stages of malignant disease (2) . The tumor-associated proteases are either secreted directly by the tumor or they originate from surrounding connective tissue and infiltrating leucocytes as a result of tumor-stroma interaction (3) .
Some tumor-associated proteases, such as matrix metalloproteinases (MMPs), cathepsines or cancer procoagulant (cP) are released into the bloodstream and can be used for diagnostic (4) (5) (6) (7) and prognostic purposes (8) . However, due to their low concentration, the detection of tumor-associated proteolytic activity in serum specimens is very challenging. Furthermore, serum has high proteolytic activity that is related to diverse
Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens:
A new approach for diagnosis of malignant disease exopeptidases (9) as well as different endoproteases (e.g., from the coagulation cascade and the complement system) (10) . Nevertheless, tumor-associated protease activity in serum specimens of cancer patients can be monitored by using specific synthetic substrates that are selectively cleaved by the protease of interest (4) (5) (6) (7) . With the use of appropriate synthetic reporter peptides (RPs) for the spiking of serum specimens, the reaction conditions that comprise of substrate concentration, incubation time and buffer composition, can be optimized and standardized accordingly. Furthermore, the proteolytic fragments accumulate to a level where they become readily detectable with mass spectrometry (6) . This approach is similar to established diagnostic assays measuring the proteolytic activity of distinct enzymes, e.g., coagulation factors (11) .
With RP spiking, the pre-analytical problems relating to sample collection, storage, and handling, can be alleviated (12) . The success of mass spectrometry-based functional endoprotease profiling with RP spiking has two essential prerequisites (6) . Firstly, the RPs must be protected from unwanted proteolytic processing by genuine serum proteases. Any cleavage of RPs by endoproteases is followed by further proteolytic degradation through exoproteases (13) . Secondly, and most importantly, suitable RPs with appropriate amino acid sequences have to be identified, that can be cleaved by tumor-associated proteases with the utmost specificity and selectivity (14) .
In this study, we present an approach for the optimization of MS-based RP profiling by modulating the cleavage site of a given RP with a positional scanning synthetic combinatorial library (PS-ScL) (15) . As a model, we have chosen the cleavage sequence, WKPYDAAD, known to be processed by the tumor-associated protease cP (10) . The positions P2, P1 and P'1 (16) were systematically varied and 24 different peptides were synthesized. Serum specimens from colorectal cancer (cRc) patients and healthy control individuals were used to analyze the peptide fragments generated by proteolytic activity using matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF-MS). The exchange of the amino acid, aspartic acid (D), in position P1' against asparagine (N) resulted in improved classification accuracy of the serum specimens from non-malignant controls and tumor patients. To alleviate interindividual differences between protease profiles (17) the optimized RP WKPYNAAD was combined with the RPs, VPLSLTMg and IPVSLRSg, that are cleaved by the tumor-associated proteases, MMP2 and MMP7, respectively (18) . In a proof-of-principle experiment with sera from cRc patients and healthy controls, the diagnostic performance could further be enhanced by multiplex assay.
Using systematic permutations of the model substrate, we investigated the specificity of protease activities in cRc patients and controls. Furthermore, the effects of combining the candidate model peptide with cleavage substrates for MMP2 and MMP7 on classification were assessed in a multiplex setting. Our results demonstrate that the optimization of RPs for MS-based functional protease profiling is crucial prior to its use in diagnostic applications. currently, although time consuming and laborious, the growing capabilities of high throughput synthesis of peptide libraries in microarray formats (19) allow for increased optimization and multiplicity.
This could lead to the development of clinically useful tests of proteomics profiling in oncology.
Materials and methods

PS-SCL and RP synthesis.
The PS-ScL was synthesized in the functional genome analysis laboratory of the german cancer Research centre (Heidelberg, germany). A 24-PSScL was developed in order to optimize the cleavage motif, WKPyDAAD, (Table I ) that is part of the coagulation factor, X heavy chain (P00742). This sequence is cleaved after the amino acid tyrosine (y) by the tumor-associated protease cP (EC 3.4.22.26) (10) and based on the work of Mielicki (20) , we decided to vary the positions P2, P1 and P1' of the cleavage motif (16) . All peptides were dissolved in DMSO as 4 mM stock solution and aliquots were kept at -20˚C until further use.
Cell culture. The human cRc cell line, HT-29, was purchased from the American Type culture collection (ATcc). cells were grown in RPMI medium that was supplemented with 10% FbS, penicillin (100 units/ml) and streptomycin (100 µg/ml) in a 24-well cell culture plate. The cells were grown at 37˚C and 5% cO 2 and harvested prior to complete confluence. The supernatant was removed from the cell culture plate and immediately centrifuged at 5000 rpm for 5 min. The cleared supernatant was stored at -80˚C until further use.
Serum samples. Whole blood specimens were acquired from patients with metastatic colorectal tumors and healthy controls at the University Hospital Mannheim. blood collection was performed after we had obtained institutional review board approval and written informed consent from all patients. After a 30-min clotting time at room temperature, the specimens were centrifuged at 20˚C for 10 min at 3000 x g. The serum was removed and aliquots were stored at -80˚C until further use. Any handling and processing of serum specimens from tumor patients and healthy controls was performed in a strictly blinded manner. Quality control (Qc) samples (pooled serum specimens from tumor patients and controls) were randomly integrated into the study and measured alongside the test samples.
PS-SCL screening with serum specimens. Each substrate was diluted to 100 µM in 2X digestion buffer (200 mM Tris-Hcl pH 7.4, 20 mM cacl 2 ). Pooled serum specimens from tumor patients and healthy controls were diluted 1:3 with PbS pH 7.4 (PAA Laboratories). Subsequently, 50 µl from 100 µM/ml substrate solutions were mixed with 50 µl 1:3 diluted serum sample and incubated at 37˚C for 2 h. Proteolytic fragments of RPs were extracted from serum specimens as previously described (6) . Briefly, streptavidin sepharose high-performance slurry (gE Healthcare) was washed twice and resuspended in PbS pH 7.4 to yield 50% slurry. We then added 50 µl of streptavidin slurry to each sample and incubated the mixture for 15 min at room temperature. After binding, the streptavidin sepharose was centrifuged at 1100 x g for 5 min. A 20 µl aliquot of the supernatant was further purified using the IMAC SL nickel magnetic beads (Bruker Daltonics) prior to MALDI-TOF-MS analysis as described previously (6) .
MALDI-TOF measurements.
We diluted 1 µl of each sample 1:10 in matrix solution, and 1 µl of the resulting mixture was spotted onto a MTP 384 polished steel target (Bruker Daltonics). MALDI-TOF-MS measurements were performed using an Autoflex II (Bruker Daltonics) operating in the positive mode. The matrix solution was prepared by dissolving 0.3 g/l of α-cyano-4-hydroxycinnamic acid solution (Bruker Daltonics) in ethanol/acetone (2:1, v/v), and external mass calibration was then performed. The MS spectra for peaks in the range of 1-3 kDa were generated by summarizing 1200 laser shots (60 shots; 20 different spot positions; hexagonal cyclic movement) and a maximal laser power of 30%. For each spectrum a peak-picking algorithm (centroid, signal-to-noise ratio >10) was applied by using FlexAnalysis software (Bruker Daltonics).
Kinetics of proteolytic processing for selected RPs. The RPs 1 and 4 from the 24-PS-ScL (Table I) were diluted to 100 µM in 2X digestion buffer (200 mM Tris-Hcl pH 7.4, 20 mM cacl 2 ). The pooled serum specimens from tumor patients (QcT) (n=5) and healthy controls (QcH) (n=5) were diluted 1:3 with PbS and the resulting 50 µl were placed in 96-well microplates (greiner). Subsequently, 50 µl from 100 µM substrate solutions were added to the pooled serum specimens and incubated at 37˚C for 0, 0.5, 1, 2, 4, 6, 8 and 16 h. The proteolytic cleavage of RPs was interrupted by freezing the spiked specimens at -20˚C prior to further processing. After incubation the resulting digests were diluted 1:10 with 0.1% TFA prior to MALDI-TOF measurements (21) .
Reproducibility of RP spiking. To monitor the reproducibility of RP spiking, two distinct quality control samples were generated, comprising of serum specimens from five colorectal tumor patients (QcT) and five healthy control individuals (QcH), respectively. both samples were aliquotted and stored at -80˚C until further use.
Each QCT and QCH sample was spiked with the RPs, RP1 and RP4, as described above. After incubation for 16 h at 37˚C the specimens were frozen at -20˚C prior to MALDI-TOF-MS analysis. The proteolytic processing of the RPs resulted in the accumulation of the anchor peptide, D-Ahx-AhxHHHHHHt [mass to charge ratio (m/z) 1283] (Table II) , and the respective peak intensities were used for quantification. The distribution of the m/z 1283 peak was visualized with whisker box plots, and standard deviation (SD) and coefficient of variation (cV) was calculated with Origin software, version 8.1.
RP validation and multiplex protease profiling in serum specimens. For validation, the optimized RP (RP4) with the cleavage site, WKPyNAAD, was compared to the original substrate (RP1) WKPyDAAD in a set of 25 serum specimens from cRc patients, 25 serum samples from patients with inflammation and high C-reactive protein but no malignant disease and 25 specimens from healthy control individuals. The RPs were diluted with 2X digestion buffer at a final concentration of 50 µM and incubated for 16 h with the serum specimens.
For multiplex protease profiling, the selected RPs from the PS-Sc library with the optimized cleavage site, WKPyNAAD (RP4), and the original substrate, WKPyDAAD (RP1), together with two other RPs (RPA and RPB) with known cleavage sites for MMP2 and MMP7, respectively (18), were chosen for this 'proof-of-principle' experiment (Table II) . The set of four RPs was incubated with 25 serum specimens from cRc patients and 25 serum specimens from healthy controls. The RPs were added to the serum specimens as described above and incubated at 37˚C for 16 h. The proteolytic cleavage of RPs was interrupted by freezing at -20˚C prior to further processing. The spiked specimens were diluted 1:10 with 0.1% TFA prior to MALDI-TOF-MS analysis (21) . 
Amino acids that differ from the original sequence of RP1 are indicated in bold letters. The reporter peptides (RPs) from group 1 (RP1-RP12) had proline in the position P2 and showed different cleavage patterns when compared to the RPs from group 2 with valine (V) at position P2 (see Fig. 1 ). The non-prime site (P4-P1) and prime site positions (P1'-P4') are labelled according to the nomenclature described by Schechter and berger (16) .
software suite. For unsupervised hierarchical clustering, the software programs, cluster and TreeView, were used (23).
Results
Optimization of RPs for CP with PS-SCL screening.
The RP with the cleavage site, WKPyDAAD, was processed by the tumor-associated protease cP (Ec 3.4.22.26) and has previously been described in the endoprotease profiling of serum specimens from cRc patients (6) . The proteasesubstrate interaction can further be optimized by the use of synthetic peptide libraries (15) . In order to incorporate diversity, amino acids of the original sequence were permuted in positions P2, P1 and P1' as described in Materials and methods (Table I) . The screening of the PS-ScL showed relatively homogeneous results for the HT-29 cell culture supernatant that has a high procoagulant activity (24) (Fig. 1) . Most RPs from group 1 with proline at position P2 (Table I) were cleaved between position P1 and P1' at the predicted site for the cysteine protease CP (10) . Specifically, the RPs, RP1, RP4 and RP11, were cleaved in culture supernatant of HT-29 cells (Fig. 1A) . In contrast, the exchange of the amino acid proline (P) versus valine (V) at position P2 of the non-prime site (group 2, Table I ) resulted in a shift of the cleavage site, and the RPs were cut between P2 (V) and P1 (Fig. 1b) . This suggests that the endoprotease processing the RPs from group 2 is different from cP. However, the exoprotease content of cell culture supernatant from cRc cells is limited (24, 25) , leaving the once-cleaved fragments stable. In contrast, serum comprises of a multitude of different proteases (9) and RPs that are first cleaved by endoproteases are further degraded by a multitude of exoproteases resulting in a 'ladder-like' degradation (6) . The prolonged incubation of RPs results in an accumulation of protease-resistant c-terminal fragments that are designated as anchor peptides (6) . Accordingly, the fragment, D-AhxAhx-HHHHHH-t (m/z 1283), is the predominant signal that resulted from the cleavage of RPs from group 1 after 2 h (Fig. 1A ) and up to 16 h of incubation (Fig. 6) . Specifically, RP4 was cleaved in the pooled serum specimen of tumor patients and the signal intensity of the anchor peptide (m/z 1283) originated from RP4 was higher when compared to RP1 or RP11 (Fig. 1A) . Most importantly, the proteolytic processing of RP4 in the pooled serum from healthy controls was weak and clearly different to the strong signal of the tumor specimen (Fig. 1A) .
In contrast, the RPs from group 2 did not show different patterns of proteolytic processing when pooled serum specimens of tumor patients and healthy controls were compared (Fig. 1b) . Furthermore, the cleavage of these RPs did not only result in the accumulation of anchor peptides, but also longer fragments wer seen, making the interpretation of results more difficult.
In summary, there is one promising RP (RP4) that showed increased signal intensities in pooled serum specimens from tumor patients when compared to healthy controls and therefore, this was selected for further validation studies.
Kinetics of proteolytic processing for RPs, RP1 and RP4, in serum specimens. The RP, RP4, as the most promising candidate from the PS-ScL screening and the original substrate, Figure 1 . Processing of 24 RPs from the PS-ScL in different specimens. RPs were incubated with cell culture supernatant from HT29 cells, and serum from CRC patients (QCT) and healthy controls (QCH) for 2 h at 37˚C prior to MALDI-TOF-MS. The signal intensities were visualised with TreeView software (23) and red colour indicates high signal intensity of the respective proteolytic fragments. (A) RPs RP1-12 (group 1, see Table I ). (b) RPs RP13-24 (group 2, see Table I ). AP, anchor peptide (see Table II ).
RP1, were chosen for further protease profiling experiments.
The RPs were incubated in serum specimens for different times ranging from 0 to 16 h in order to determine the optimal incubation time. Two pooled serum specimens, one from cRc patients (QcT) and the other from healthy controls (QcH) were spiked with RP1 and RP4 and MALDI-TOF-MS analyses were performed in triplicate for each time-point. Signal intensities of the peptide fragment, D-Ahx-Ahx-HHHHHHt (m/z 1283), were extracted from the MS spectra. The ratio of the mean signal intensity of the m/z 1283 peak in tumor and control samples (QcT/QcH) was calculated for each incubation time-point (Fig. 2) . In the QcT and QcH specimens, no differences were observed in the proteolytic processing of RP1 or RP4 for up to 8 h of incubation. In contrast, after 16 h of incubation there was a 2-fold stronger proteolytic processing of RP1 and RP4 in the pooled serum specimen from tumor patients (QcT). Accordingly, incubation times of 16 h were chosen for all further experiments.
Although the QcT/QcH-ratios for signal intensities of the m/z 1283 peak resulting from the cleavage of RP1 and RP4 were almost identical, we noted that RP4 processing gave consistently higher signals when compared to RP1. After 16 h of incubation of RP4, the mean signal intensities of the proteolytic product (m/z 1283) were 6.983 arbitrary units (a.u.) and 3.567 a.u. for the QcT and QcH specimens, respectively. In contrast, the incubation of the same serum specimens with RP1 resulted in mean signal intensities of 2.357 a.u. for QcT specimens and 1.383 a.u. for QcH specimens (Fig. 3) . In general, higher signal intensities are favourable for the good reproducibility of MALDI-TOF-MS measurements as demonstrated below.
Reproducibility of RP spiking.
To test the reproducibility of RP spiking, we analyzed two serum samples (QCT, QCH) ten times with independent sample preparation, MALDI-TOF-MS measurement and data analysis for every specimen. The RPs, RP1 and RP4, were added to the serum specimens and incubated for 16 h as described above.
The CV for reproducibility of RP1 spiking was 53.3% (mean 1.383 a.u., SD 787) for the QcH sample and 22.2% (mean 2.357 a.u., SD 523) for the QcT sample. In contrast, the reproducibility of RP spiking with RP4 showed higher signal intensities with better reproducibility. The cV for reproducibility of RP4 spiking was 15.5% (mean 3.567 a.u., SD 553) for the QcH sample and 12.8% (mean 6.983 a.u., SD 895) for the QcT sample. The QcT samples could clearly be separated from QCH samples by the use of RP4 as well as RP1 spiking (Fig. 3) .
Clinical validation of optimized RP4 in a sample cohort. The RPs, RP1 and RP4, were further validated with serum specimens from 25 cRc patients, 25 patients without malignancy but high CRP levels and 25 healthy controls. The spiked serum specimens were incubated for 16 h at 37˚C prior to MALDI-TOF-MS analysis as described in Materials and methods.
For both RPs (RP1 and RP4) the signal intensities of the corresponding anchor peptides (m/z 1283) were significantly higher in the tumor specimens when compared to the healthy controls (Fig. 4) . For RP1, the mean value of signal intensity for the m/z 1283 peak was 3.486 a.u. in the specimens from healthy controls and 2.59-fold higher (9.041 a.u.) in the specimens from cRc patients. Accordingly for RP4, the mean value was 7.974 a.u. in the specimens from healthy controls and 2.78-fold higher (22.187 a.u.) in the specimens from cRc patients. However, only RP4 but not RP1 could additionally discriminate serum specimens from tumor patients and patients without malignant disease but high cRP levels. The mean value for the signal intensity of the anchor peptide (m/z 1283) originated from RP4 in serum specimens of cRc patients was 22.187 a.u. whereas in serum specimens from patients with non-malignant disease but high cRP levels, the mean value was only 10.382 a.u. and this difference was statistically significant with a p-value of <0.05. In contrast, the mean value for the signal intensity of the anchor peptide (m/z 1283) originated from RP1 in serum specimens of cRc patients was only 9.041 a.u. and statistically not different (p-value of 0.214) to the mean value of 7.925 a.u. in serum specimens from patients with non-malignant disease but high cRP levels (Fig. 4) .
Functional protease profiling with different RPs (multiplex analysis).
In order to test the hypothesis that the combination of different RPs can improve the diagnostic classification of tumor samples (26) , two additional RPs were added to the protease profiling experiments. besides the RPs, RP1 and RP4, that are cleaved by the cysteine protease 'cancer procoagulant', we selected two RPs designated as RPA and RPb (Table II) that are known to be cleaved by the tumor-associated proteases, MMP2 and MMP7, respectively (18) . RPA and RPb were also added to the serum specimens of 25 cRc patients and 25 healthy controls, incubated for 16 h and analysed with MALDI-TOF-MS. The signal intensities of the anchor peptides (Table II) were extracted from the MS spectra for ROc curve calculations and multiparametric analyses with cluster and TreeView software (23) . The area under the ROc-curves (AUc) for the single markers ranged from 0.55 (RPB) to 0.86 (RPA). However, the highest AUc value of 0.90 was observed for the combination of all 4 RPs (RP1, RP4, RPA and RPb).
The unsupervised hierarchical clustering resulted in diagnostic sensitivity and a specificity of 84%, meaning that 4 out of the 25 specimens from the colorectal tumor patients were classified as false-negative and 4 out of the 25 specimens from the healthy controls were classified as false-positive (Fig. 5) .
Discussion
The dysregulation of protease activity plays an important role in the initiation and progression of malignant disease (1,2). Tumor-associated proteases that are secreted into the bloodstream are candidates for laboratory diagnostic use (6, 7, 13) . Adding RPs to serum specimens allows for the monitoring of tumor-related proteolytic activity (5-7). Most importantly, the RP spiking can easily be standardized and thereby alleviates major limitations of current MS-based clinical proteomic profiling approaches (4, 6, 12) . However, blood serum has a high intrinsic proteolytic activity (9) , and successful protease profiling analyses should therefore depend on the selection of adequate RPs, exclusively cleaved by tumor-associated proteases and not by intrinsic serum proteolytic activities.
In a previous study, we developed a RP with the cleavage motif, WKPyDAAD, for the MS-based detection of the tumor-associated cysteine protease 'cancer procoagulant' (6). The aim of our present study was to further optimize the diagnostic sensitivity and specificity of RP spiking by systematically varying the amino acid sequence of the cleavage motif, WKPYDAAD, in order to improve the classification accuracy of tumor samples. For this purpose, a PS-ScL was constructed. Over the years, a number of studies have demonstrated the power of PS-ScL to effectively optimize protease-substrate interactions, when the proteases are available in highly purified forms (15, 27, 28) . However, the use of PS-ScL has not been reported for the screening of protease activity in clinical specimens so far, in which the enzymatic activities are far more complex. For example, several synthetic peptidyl substrates for the tumor-associated protease cP have been described (29) . However, these substrates are also cleaved by other high abundance proteases of serum specimens and are therefore of limited use for diagnostic purpose for detecting cP activity in clinical specimens.
The in vitro stability of RPs in human serum specimens from non-malignant controls is a most critical issue and often decreases the diagnostic specificity of functional protease profiling (14) . Furthermore, the peptidyl substrates should have a high affinity for tumor-associated proteases to warrant high diagnostic sensitivities. Some of the amino acid substitutions of the cleavage motif, WKPyDAAD, are associated with dramatic effects concerning the processing of the RP in serum specimens from tumor patients and healthy controls. The exchange of proline (P) against valine (V) at position P2 led to a complete loss of diagnostic specificity and the RPs were cleaved in serum specimens from tumor patients and healthy controls in a nearly identical manner. Proline (P) is a cyclic and hydrophobic amino acid that is disrupting protein conformation whereas valine (V) with its aliphatic side chain is highly hydrophobic (30) . It can be concluded that proline at position P2 is essential for the cleavage related to the activity of cP (20) . In contrast, valine at position P2 induces the processing of RPs by obviously genuine serum proteases.
When amino acids with similar physicochemical properties were substituted at positions P1 (aromatic amino acids y, W, and F) and P1' (acidic/polar amino acids D, E, Q, N), the proteolysis rate of RPs, that affects diagnostic sensitivity, could further be improved and the sequence motif, WKPyNAAD (RP4), turned out to be more effective than the original sequence WKPyDAAD (RP1). We were not able to perform enzyme kinetic measurements, as analyses were performed with clinical specimens that comprised of a multitude of different proteases. However, in a cohort of 25 specimens from tumor patients, the proteolytic processing of the RP, RP4, with a median signal intensity of 22.187 a.u. was approximately 2-fold higher than the corresponding value of 9.041 a.u. for the RP, RP1 (Fig. 4) . These data indicate that the exchange of aspartic acid (D) against asparagine (N) at the position P1' of the sequence WKPyDAAD induces a faster cleavage by the tumor-associated protease cP. More importantly, the proteolytic processing of the RP, RP4, in serum specimens from tumor patients was also clearly above the level of the median signal intensity of 10.382 a.u. observed in serum specimens from patients with non-malignant but inflammatory disease. In contrast, the proteolytic processing of the RP, RP1, was not statistically different in specimens from cRc patients and patients with inflammatory disease (Fig. 4) . The proteolytic activity of serum specimens is not only altered in malignant disease, but also during inflammatory processes (31, 32) and it is obvious that specific tumor-associated proteolytic activity could be detected with the improved RP, RP4, but not with RP1.
However, few outliers of the healthy control individuals showed high signal activity for the cleaved RPs, RP1 and RP4, hypothesized to be surrogate markers for CP activity. This, in part, could be due to the fact that cP is not exclusively present in serum specimens from tumor patients, but can also be found in serum specimens from healthy control individuals (33). It could also be possible that the RP can also be cleaved by other endoproteases, thereby resulting in the decreased diagnostic specificity of the test. Furthermore, a recent imaging study showed incidental findings in a substantial number of participants, which resulted in further treatment such as surgery, for a previously undiagnosed tumor (34) . This highlights the problem that in a 'healthy' control population, there could be a few cases of undetected malignancy, thereby overestimating diagnostic unspecificity. In contrast, some cancer patients had low signal intensities for the cleaved RPs, RP1 and RP4, indicating no increased activities of cP (Fig. 5) , resulting in low diagnostic sensitivities in these cases.
It is likely that tumor heterogeneity and the progression of malignant disease result in different protease patterns (17, 35) . The use of one single RP is unlikely to be sufficient to ensure high diagnostic accuracy, thus calling for combinations of different RPs in a multiplex fashion. For example, MMP2 and MMP7 are known to play important roles in the progression of cRc (2). Our approach to combine RP1 and RP4, RPA Table II ). Asterisks indicate proteolytic fragment with highest signal intensity.
(MMP2) and RPb (MMP7) resulted in improved AUc for ROc curves, indicating that multiplex analysis has superior diagnostic efficacies (36) .
While our approach shows the methodological feasibility of designing protease profiling assays, it requires validation in studies within a clinical setting to comply with recent recommendations (37) , before inclusion in diagnostic procedures. Further studies are required in order to focus on the systematic identification of RP sequences that are most efficiently and specifically cleaved by tumor-associated proteases. Furthermore, the characterization and identification of proteases involved in the processing of RPs is also essential for improving sample collection and storage for the preservation of tumor-associated protease activity.
Finally, MALDI-TOF-MS has two serious shortcomings as regards functional protease profiling for diagnostic use. Firstly, the combination of different RPs for multiplex analysis has to be evaluated carefully, as the unwanted phenomenon of ion suppression has to be taken into account (38) . Secondly, signal intensities of MALDI-TOF-MS analyses have unsatisfactory interday reproducibility that is hardly acceptable for routine analyses (39) and we therefore suggest, that protease profiling should be evaluated with LC/MS/MS technology (40) which would allow for the exact quantification of multiple analytes within a single run.
